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Recently, ID-1 (inhibitor of differentiation/DNA binding) is
suggested as an oncogene and is reported to promote cell prolif-
eration, invasion, and survival in several types of human cancer
cells through multiple signaling pathways. However, how Id-1
interacts with these pathways and the immediate downstream
effectors of the Id-1 protein are not known. In this study, using a
yeast two-hybrid screening technique, we identified a novel
Id-1-interacting protein, caveolin-1 (Cav-1), a cell membrane
protein, andapositive regulator of cell survival andmetastasis in
prostate cancer. Using an immunoprecipitation method, we
found that the helix-loop-helix domain of the Id-1 protein was
essential for the physical interaction between Id-1 andCav-1. In
addition, we also demonstrated that the physical interaction
between Id-1 and Cav-1 played a key role in the epithelial-mes-
enchymal transition and increased cell migration rate as well as
resistance to taxol-induced apoptosis in prostate cancer cells.
Furthermore, our results revealed that this effect was regulated
by Id-1-induced Akt activation through promoting the binding
activity between Cav-1 and protein phosphatase 2A. Our study
demonstrates a novel Id-1 binding partner and suggests a
molecularmechanism thatmediates the function of Id-1 in pro-
moting prostate cancer progression through activation of the
Akt pathway leading to cancer cell invasion and resistance to
anticancer drug-induced apoptosis.
Id-1 (inhibitor of differentiation and DNA binding) is a
member of the helix-loop-helix (HLH)3 transcription factor
family. It lacks a basic domain for DNA binding; therefore, it
acts as a dominant inhibitor of the basic HLH transcription
factors by forming heterodimers. Id-1 has multiple functions,
including inhibition of differentiation, induction of prolifera-
tion, and delaying replicative senescence (1). In addition, ID-1
has been suggested as a potential oncogene, because it is up-
regulated in many types of human cancer such as breast (2),
pancreas (3), cervical (4), and prostate cancers (5). Id-1 expres-
sion levels are positively associated with poor clinical outcome
and drug resistance (4, 6, 7). For example, early stage cervical
cancer patients with increased Id-1 expression showpoor prog-
nosis (4). In breast and ovarian cancer patients, enhanced Id-1
expression is correlated with more aggressive behavior as well
as much shorter overall survival (6, 7). These lines of evidence
suggest that Id-1 plays a positive role in promoting the devel-
opment and progression of human cancer.
In addition to itswell described role in cell proliferation (8, 9),
recently, Id-1 has been reported to promote survival and met-
astatic ability of cancer cells. For example, overexpression of
the Id-1 protein enhances invasive properties of hematopoietic
cell lines through transactivation of the matrix metalloprotein-
ase 9 transcription (10). In addition, Id-1 mediates transform-
ing growth factor--induced epithelialmesenchymal transition
(EMT), a process by which epithelial cells obtain mesenchymal
features and show reduced cell-cell contact and motility, and is
suggested to play a critical role during invasion and metastasis
(11). Constitutive expression of the ID-1 promoter as a result of
loss of the NF-1/Rb/HDAC-1 transcription repressor complex
is also found in metastatic breast cancer cells (12). Previously,
we have observed in prostate cancer cells that ectopic expres-
sion of Id-1 promotes the growth of endothelial cells (13), sug-
gesting its positive role in promoting angiogenesis. Recently, we
andothers have demonstrated that Id-1 is able to protect cancer
cells against a variety of anticancer drug-induced apoptosis in
several types of human cancer cells, including cervical, breast,
prostate, and nasopharyngeal carcinomas (14). These results
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are consistent with the reports on breast and gastric cancers
that increased Id-1 expression is associated with highly aggres-
sive phenotypes in both cell lines and animalmodels (15, 16). In
combination with the evidence that Id-1 overexpression is fre-
quently found in advanced cancers (6, 7), it is possible that the
positive role of Id-1 in cancer metastasis and survival may pro-
vide an advantage for the progression of human cancer leading
to poor clinical outcome.
Several signaling pathways have been suggested to mediate
the function of Id-1. For example, the Id-1-induced invasion
ability in breast cancer cells is mediated through induction of
the expression of a 120-kDa gelatinase, a type IV collagenase
matrix metalloproteinase family member (17). Matrix metallo-
proteinase 9 activation is found to be responsible for the Id-1-
induced increased invasive ability in leukemia cells (10), sug-
gesting that Id-1 plays a positive role in activation of the
cell-matrix adhesion signaling pathway. In addition, Id-1 has
been reported to be involved in the down-regulation of E-cad-
herin expression and reorganization of-catenin and F-actin as
well as in transforming growth factor--induced EMT in sev-
eral cell types (11, 18), suggesting that it promotes metastatic
ability throughmodification of the cell adherens junction com-
plex. On the other hand, Id-1 is able to protect anticancer drug-
induced apoptosis through activation of NF-B and Raf/MEK
and suppression of JNK pathways in prostate cancer and other
types of cancer cells (19–22), indicating its ability to regulate
multiple cell signaling pathways. However, it remains unknown
as how Id-1 interacts with these pathways and what are the
immediate downstream effectors of the Id-1 protein that medi-
ate its interaction with cell signaling pathways. In this study, we
report that by using yeast two-hybrid screening technique, we
identified a novel Id-1 interacting protein, caveolin-1 (Cav-1),
an integral cell membrane protein that interacts with multiple
signaling molecules and regulates signaling transduction (23).
In addition, we found that the HLH domain of the Id-1 protein
was responsible for the interaction between Id-1 andCav-1.We
also demonstrate that the physical interaction between Id-1
and Cav-1 was essential for the positive role of Id-1 in inducing
EMT and cell survival in prostate cancer cells. Furthermore,
our results suggested that the Id-1-induced Akt activation
through promoting the binding activity between Cav-1 and
PP2Awas accountable for its function as a promoter of prostate
cancer cell invasion and resistance to anticancer drug-induced
apoptosis.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screening for Id-1 Binding Candidates—A
cDNA library was established from a human nonmalignant
prostatic epithelial cell line, Hpr-1 (24), and cloned into the
prey vector pGAD424, using the SMARTTM cDNA library con-
struction kit (Clontech). The full-length ID-1 cDNAwas cloned
into the bait vector pAS2-1. The bait and prey constructs were
co-transfected into the Saccharomyces cerevisiae strain
CG-1945 using the YEASTMAKERTM yeast transformation
system 2 kit (Clontech). Positive clones were selected in the
medium-stringency medium, SD/His/Leu/Trp, and
galactosidase assay using the MATCHMAKER GAL4 two-
hybrid system 3 and Libraries kit (Clontech). The positive
plasmids were recovered using a plasmid extraction kit
(YEASTMAKERTM yeast plasmid isolation kit, Clontech),
transformed into Escherichia coli for plasmid amplification
and sequencing for identity, respectively.
Cell Culture and Drugs—Two human prostate cancer cell
lines, LNCap, obtained from American Type Culture Collec-
tion (Manassas, VA), and 22RV1, kindly provided by Prof. F. L.
Chan (Chinese University of Hong Kong), were maintained in
RPMI 1640 medium (Sigma) supplemented with 5 or 10% (v/v)
fetal calf serum, respectively, penicillin (100 units/ml), and
streptomycin (100 g/ml) at 37 °C, 5% CO2. The anti-cancer
drug, taxol, PI3K/Akt specific inhibitors, LY294002 and wort-
mannin (Calbiochem; dissolved inMe2SO), were diluted in cul-
ture medium to obtain the desired concentrations.
Plasmids and Transient Transfection—HA-tagged CAV-1
was generated using the following primers: forward, 5-ATTA
GGA TCC ATG TCT GGG GGC AAA TAC-3, and reverse,
5-ATTA GGA TCC ATG TAC CCA TAC GAT GTT CCA
GAT TAC GCT TCT GGG GGC AAA TAC GTA G-3. The
PCR products were then cloned into the pcDNA3.1 vector. The
vector expressing the FLAG-tagged wild type Id-1 (WT-ID-1)
was described previously (25), and FLAG-tagged truncated
ID-1 vectors were generated from the WT-ID-1 and then
cloned into the pcDNA3.1 vector. The vectors expressing
FLAG-tagged Id-1 site-directed mutants were generated using
a site-directed mutagenesis kit (Stratagene, La Jolla, CA) with
procedures described by the manufacturer. The resulting con-
structswere confirmedby sequencing and then transfected into
cells using FuGENE6 reagent (RocheDiagnostics). The Si-Con,
Si-Id-1, and Si-Cav-1 were synthesized commercially by
siGENOMETM (Dharmacon). The targeting sense sequences
are as follows: Si-ID-1, UAAACGUGCUGCUCUACGA; Si-
CON, UAAGGCUAUGAAGAGAUAC; Si-CAV-1 (a mix-
ture of 4): Si-Cav-1-1, CUAAACACCUCAACGAUGA;
Si-Cav-1-2, GCAAAUACGUAGACUCGGA; Si-Cav-1-3,
GCAGUUGUACCAUGCAUUA; and Si-Cav-1-4, GCAU-
CAACUUGCAGAAAGA (ON-TARGET plus SMARTpool
Human Cav-1). They were transiently transfected into cells
with Lipofectamine according to the protocols described
before (21).
Western Blotting—Detailed experimental procedures were
described previously (21). The primary antibodies used were as
follows: Id-1, Cav-1, N-cadherin, -actin (Santa Cruz Biotech-
nology), E-cadherin, -catenin, -catenin, GSK3 (BD Bio-
sciences), p-Akt, Akt, p-GSK3 (Cell Signaling Technology),
-SMA, vimentin, FLAG, HA (Sigma), and PP2A-C subunit
(Upstate Biotechnology, Inc.).
Immunoprecipitation—Cells were lysed in RIPA buffer 48 h
after transfection. Immunoprecipitation was performed with
the FLAG HA tandem affinity purification kit (Sigma). Briefly,
cell lysates were incubated with anti-FLAGM2 affinity resin or
anti-HA-agarose affinity resin overnight. The resin was then
washed three times with lysis buffer. The complex on the anti-
FLAGM2 affinity resin was eluted with 3FLAG peptide (150
ng/ml), and the complex on anti-HA-agarose affinity resin was
eluted with urea (8 M) for 30 min at 4 °C. The eluted complex
was loaded onto SDS-PAGE for Western blotting analysis,
using the procedures described above.
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For endogenous immunoprecipitation, cell lysate was pre-
cleared by incubation with protein G-agarose beads and rabbit
IgG for 1 h at 4 °C and then incubated with anti-Cav-1 (Santa
Cruz Biotechnology) overnight at 4 °C. The protein G-agarose
beadswere then added into the cell lysate and further incubated
for 2 h. The beads were then washed with RIPA buffer and
boiled with 2 sample buffer for 10 min at 100 °C. The super-
natant was loaded onto as SDS-PAGE for Western blotting
analysis.
RT-PCR—Total RNA was isolated from cells using TRIzol
reagent according to the manufacturer’s protocol (Invitrogen).
For RT-PCR, cDNAs were synthesized using the Super-
ScriptTM first strand synthesis system (Invitrogen) and then
amplified by PCR with E-cadherin-specific primers as
described previously (26). The PCR conditions were as follows:
an initial denaturation at 95 °Cwas followed by 28 cycles of PCR
(94 °C for 1min, 56 °C for 1min, and 72 °C for 1min) and a final
extension at 72 °C for 5min.GAPDHwas amplified as an inter-
nal loading control. PCR products were electrophoresed on
1.5% agarose gels and analyzed using a gel documentation sys-
tem (UVP, LLC, Upland, CA).
Luciferase Assay—Cells were plated into a 24-well plate at a
density of 5  104 cells per well and were co-transfected with
pGL2-Basic-Ecad1359 (kindly provided by Dr. KarenM. Habra
and Dr. Amy S. Woodard, Departments of Internal Medicine,
Human Genetics, and Pathology, University of MichiganMed-
ical School) (27), pRL-CMV-Luc (internal control), WT-Id-1,
or truncated Id-1 (FLAG-CT60-Id-1) and Cav-1, respectively.
After 48 h, the cells were lysed and assayed for luciferase activity
using the dual-luciferase reporter assay system (Promega, WI).
Each data point represents the mean of three experiments, and
error bars indicate the standard deviation.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bro-
mide (MTT) Assay—Cell viability was measured using a MTT
proliferation assay kit, and the detailed procedures were
described previously (21).
Immunofluorescent Staining—Cells were fixed with 4%
paraformaldehyde and washed with 1 phosphate-buffered
saline. The cells were incubated with a primary polyclonal
antibody against Id-1, a TRITC-labeled secondary antibody
against rabbit IgG (DakoCytomation), a primary monoclonal
antibody against Cav-1 (BD Biosciences), and a fluorescein
isothiocyanate-labeled secondary antibody against mouse
IgG (DakoCytomation), respectively, or the cells were incu-
bated with primary antibodies against E-cadherin or -cate-
nin (BD Biosciences), respectively, and then were incubated
with a fluorescein isothiocyanate-labeled secondary anti-
body against mouse IgG (DakoCytomation). Signals were
visualized and captured using a fluorescent microscope
under 400 magnifications.
Wound Closure Assay—Detailed experimental procedures
were described previously (26). Cell migration rate was gener-
ated as follows. The vertical distance between two borderlines
of the wound was measured, and the distance was set up as 1.0
at time 0h in each cell line. Cellmigration ratewas calculated by
dividing the distance between two borderlines at indicated
experimental time points and time 0 h.
Protein Phosphatase 2A Activity Assay—The PP2A activity
wasmeasured using a PP2A immunoprecipitation phosphatase
assay kit with the procedures described by the manufacturer
(Upstate Biotechnology, NY). Briefly, cells were lysed with
phosphatase lysis buffer described as before (28) and incubated
with a monoclonal antibody against PP2A-C subunit and the
protein A-agarose slurry for 1 h. The agarose beads were then
washed twicewith phosphatase lysis buffer and oncewith phos-
phatase assay buffer. PP2A activitywas determined using amal-
achite green phosphatase assay protocolwith a phosphopeptide
(KRpTIRR) as the substrate, followed by the measurement of
absorbance at 650 nm. Results represented the OD ratio
between the transfected cells and the untransfected controls.
Each data point represented the mean S.D.
RESULTS
Identification of an Id-1 Interacting Protein, Caveolin-1—To
identify novel Id-1 interacting proteins, we used a full-length
Id-1 cDNA as a bait to screen a cDNA library derived from
an immortalized human nonmalignant prostatic epithelial cell
line, Hpr-1, using the yeast two-hybrid technique. Sixteen pos-
itive clones were selected (data not shown). Sequence analysis
and data base comparison revealed that one positive clone had
100% identity to the Homo sapiens caveolin-1 mRNA coding
sequence (GenBankTM accession number NM_001753). It
encodes a cell membrane protein, caveolin-1 (Cav-1), a subunit
of caveolins that are necessary for caveolae formation, and has
been reported to regulate the signaling of membrane proteins
such as epidermal growth factor receptor, Src, and H-ras
through direct physical interaction (23). Previously, it has been
reported that similar to the Id-1 expression patterns in prostate
cancer (5, 29, 30), Cav-1 is up-regulated in metastatic prostate
cancer specimens, and its expression levels are correlated pos-
itively with Gleason Score (31). Therefore, we hypothesized
that interaction between Id-1 and Cav-1 may play a role in
mediating the oncogenic function of Id-1 in prostate cancer.
To confirm the in vivo interaction between Id-1 and Cav-1,
expression vectors containing Id-1-FLAG and Cav-1-HA were
co-transfected into a prostate cancer cell line, LNCap, and
the cells transfected with Cav-1-HA alone were used as a neg-
ative control. As shown in Fig. 1A,Western blotting analysis on
total cell lysates showed thatHAwas detected in the cells trans-
fected with Cav-1-HA (Fig. 1A, lane 1, upper panel), whereas
both HA and FLAG were detected in the cells transfected with
Id-1-FLAG  Cav-1-HA (lane 2), indicating successful
expression of both proteins. After immunoprecipitation with
anti-FLAG M2 affinity resin, Cav-1-HA was detected in the
precipitates derived from the cells co-transfected with both
Id-1-FLAG and Cav-1-HA (Fig. 1A, lane 4), indicating co-im-
munoprecipitation of Cav-1 with Id-1. Reciprocally, after
immunoprecipitation with anti-HA-agarose affinity resin (Fig.
1A, lower panel), Id-1-FLAGwas detected in the cells co-trans-
fectedwith the twoproteins (lane 8), confirming the interaction
between Cav-1 and Id-1. To confirm these results, two prostate
cancer cell lines with relatively high levels of Id-1 and Cav-1
were used to repeat the immunoprecipitation experiments (Fig.
1B, left panel). As shown in Fig. 1B (lanes 3 and 6), the endog-
enous Id-1 was detected in the immunoprecipitates by an anti-
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Cav-1 antibody in both cell lines, further suggesting an interac-
tion between these two proteins. In addition, fluorescent
immunostaining also showed that both Id-1 and Cav-1 were
co-localized in the cytoplasm of Hpr-1 cells (Fig. 1C). Taken
together, these results suggest a physical interaction between
Id-1 and Cav-1.
To identify the binding domain of Id-1 to Cav-1, we con-
structed three vectors expressing truncated forms of Id-1,
FLAG-NCT20-Id-1 (20 amino acids deleted from N and C ter-
mini, respectively), NT71-Id-1-FLAG (71 amino acids deleted
from N terminus), and CT60-Id-1-FLAG (60 amino acids
deleted from C terminus) (Fig. 1D). These three ID-1 truncates
and the wild type ID-1 were then co-transfected, respectively,
with CAV-1-HA into LNCap cells, and the whole cell extracts
were immunoprecipitatedwith anti-FLAGM2affinity resin. As
shown in Fig. 1E, all the FLAG-tagged Id-1 proteins were
detected in the precipitates (lanes 2–5, lower panel), indicating
successful immunoprecipitation of the FLAGprotein. TheCav-
1-HA, however, was only detected in the cells expressing
WT-Id-1-FLAG and FLAG-NCT20-Id-1, which contained an
intact HLH domain of the Id-1 protein (Fig. 1E, lanes 2 and 3,
upper panel). These results demonstrate that the HLH domain
of the Id-1 protein may be essential for the interaction between
Id-1 and Cav-1. To further study the importance of the HLH
domain in the binding activity, we constructed four Id-1
mutants containing point mutations, in which one of the con-
served amino acids in the HLH domain was mutated (Fig. 1D).
Then these mutants were co-transfected, respectively, with
Cav-1-HA into LNCap cells, and immunoprecipitation was
performed using anti-FLAGM2 affinity resin. As shown in Fig.
1E, Cav-1-HA was detected in all of the precipitates (lanes
7–11, upper panel), indicating that one amino acid alteration in
the HLH domain is not sufficient to completely destroy the
binding activity of Id-1 toCav-1.However, the binding between
FIGURE 1. Id-1 interacts with Cav-1. A, co-immunoprecipitation analysis of Id-1 and Cav-1 in LNCap cells. Expression vectors containing ID-1-FLAG and
CAV-1-HAwere co-transfected into LNCapcells, and cells transfectedwithCAV-1-HAor ID-1-FLAG alonewereusedasnegative controls, respectively. Cell lysates
were immunoprecipitated (IP)with anti-FLAGaffinity resin andblottedwithanti-HAandanti-FLAG (toppanel) or anti-HA-agaroseaffinity resin andblottedwith
anti-FLAG or anti-HA (bottom panel), respectively. Note that Cav-1-HA co-immunoprecipitates with Id-1-FLAG (lane 4, upper panel), and vice versa (lane 8,
bottom panel). B, immunoprecipitation analysis of endogenous Id-1 and Cav-1 in DU145 and PC3 cells. Left panel, Western blotting (WB) analysis of Id-1 and
Cav-1 expression. Right panel,Western blotting analysis of Id-1 expression in cell lysate immunoprecipitated with an anti-Cav-1 antibody. C, immunofluores-
cent staining of Id-1 and Cav-1. Hpr1 cells were fixed and stained with anti-Id-1 rabbit polyclonal antibody and anti-Cav-1 mouse monoclonal antibody and
processed for fluorescent microscope imaging. Top left, immunofluorescent staining shows cytoplasmic localization of Id-1; top right, immunofluorescent
staining shows the localization of Cav-1, and the bottom left shows cell nuclear staining by 4,6-diamidino-2-phenylindole (DAPI). Merged fluorescent image
indicates cytoplasmic co-localization of Id-1 and Cav-1. Photos were taken under400 magnifications. D, structure of FLAG-tagged truncated and mutated
Id-1 constructs. Three truncated Id-1s, FLAG-NCT20-Id-1 (20 amino acids deleted from N- and C-terminals), NT71-Id-1-FLAG (71 amino acids deleted from N
terminus), and FLAG-CT60-Id-1 (60 amino acids deleted from C terminus), and four Id-1 mutants, Id-1(Y67D)-FLAG, Id-1(L76H)-FLAG, Id-1(K91E)-FLAG, and
Id-1-(Y101D)-FLAG, were generated. E, co-immunoprecipitation analysis of Id-1 mutants and Cav-1. Expression vectors containing FLAG-tagged truncated or
point-mutated ID-1 and CAV-1-HA were co-transfected into LNCap cells, and cell lysates were immunoprecipitated with anti-FLAG affinity resin and blotted
with anti-HA and anti-FLAG, respectively. Note that Cav-1-HA only co-immunoprecipitates with FLAG-NCT20-Id-1 (lane 3, upper panel) and FLAG tagged
WT-Id-1 (lane 2 upper panel), whereas all the FLAG-tagged point-mutated Id-1s co-immunoprecipitate with Cav-1-HA (lanes 7–11, upper panel).
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seemed much weaker than the wild
type Id-1 and the other mutants,
suggesting that the Tyr-101 amino
acid may be important for the bind-
ing activity of Id-1 to Cav-1. Taken
together, these results suggest that
the HLH domain of Id-1 is essential
for its interaction with Cav-1, and
that point mutations in the HLH
domain are not sufficient to com-
pletely abolish its binding activity to
Cav-1.
Interaction between Id-1 and
Cav-1 Is Essential for Id-1-induced
EMT—It has been reported that
both Id-1 and Cav-1 play a positive
role in metastatic progression of
prostate cancer (30, 32). It is possi-
ble that the interaction between
these two proteinsmay play a role in
their effect on the invasion ability of
prostate cancer cells. Therefore, we
next studied the significance of
Id-1-Cav-1 interaction inmediating
Id-1-induced EMT, a shift in pro-
tein expression from epithelial to
mesenchymal markers and a key
process in promoting invasion and
metastasis of cancer cells (33). Two
prostate cancer cell lines, LNCap
and 22RV1, were used in this study
because Id-1 expression could be
modified with different culture con-
ditions. Under serum-free culture
conditions, these two lines showed
low or undetectable Id-1 and Cav-1
expression so that the effect of
ectopic expression of both proteins
could be studied. As shown in
Fig. 2A, WT-Id-1  Cav-1, FLAG-
CT60-Id-1 (the no-binding Id-1
mutant)  Cav-1, as well as Id-1 or
Cav-1 alone controls were success-
fully transfected into these two cell
lines. Then the expression levels of
three epithelial markers, E-cadherin,
-catenin, and -catenin, and three
mesenchymal markers, N-cadherin,
-smooth muscle actin, and vimen-
tin, were examined by Western blot-
ting. As shown in Fig. 2B, WT-ID-1
andCAV-1 transfection alone were able to modify the expression
of both epithelialmarkers andmesenchymalmarkers (lanes 1 ver-
sus 2 or 3 for LNCap; lanes 6 versus 7 or 8 for 22RV1), suggesting
that each of them alone is able to promote EMT. However, in the
cells transfected with WT-ID-1  CAV-1, the decreased expres-
sion of epithelial markers, especially E-cadherin and -catenin,
and increased expression of mesenchymal markers, especially
N-cadherin and vimentin, were much more significant (high-
lighted) compared with either the control (Fig. 2B, lane 1) or the
cells transfectedwith ID-1 (lanes 2 and7) orCAV-1 (lanes 3 and8)
alone. In contrast, this effect was partially reversed in the cells
transfected with CT-60-ID-1  CAV-1 (Fig. 2B, lanes 4 versus 5
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and 9 versus 10). These results indicate that the interaction
between Id-1 and Cav-1 is important for a synergistic effect on
promoting EMT.
Because the membrane localization of cell adhesion mole-
cules such as E-cadherin is essential for its biological function
(35), next we performed immunofluorescent staining to exam-
ine the re-distribution of E-cadherin and its membrane com-
plex -catenin. As shown in Fig. 2C, E-cadherin and -catenin
stainingwas detectedmainly in the cytoplasm of the cells trans-
fected with WT-ID-1  CAV-1 (panel 4), whereas positive
staining was found in the cell membrane region in vector con-
trol cells (panel 1) and cells transfected with ID-1 (panel 2) or
CAV-1 (panel 3) alone. In the FLAG-CT60-Id-1Cav-1 trans-
fectants (Fig. 2C, panel 5), membrane staining was also
detected. These results indicate that the interaction between
Id-1 and Cav-1 may be able to promote subcellular re-distribu-
tion of E-cadherin and -catenin proteins. To study if the Id-1
Cav-1-induced EMTplayed a positive role on cellmigration, we
performed wound closure assay. As shown in Fig. 2D, theWT-
Id-1  Cav-1 transfectants showed the fastest migration rate,
evidenced by the lowest distance ratio between wound gap at
the 28- and 0-h experimental time point (panel 4, distance ratio
to 0 h 0.2) among all the cell lines (panels 1–3, distance ratio
to time 0 h 0.5). However, the migration rate was lower
in the cells transfected with FLAG-CT60-Id-1  Cav-1 (panel
5; distance ratio to time 0 h  0.6). These results suggest that
the Id-1-induced cell migration ability is enhanced through its
interaction with Cav-1.
To further confirm the effect of Id-1 and Cav-1 on EMT and
cell migration, the expression of Id-1 and Cav-1 was down-
regulated using small interfering RNA technology, and the
effect on EMT and cell migration was studied on the PC3 cell
line that showed relatively high levels of both proteins (Fig. 1B,
left panel). After transfecting with si-ID-1 si-CAV-1 (Fig. 2E,
lane 4), the expression of epithelialmarkerswas increased com-
pared with the cells transfected with si-ID-1 (lane 2) or
si-CAV-1 (lane 3) alone or si-CON (lane 1), which was corre-
lated with decreased expression ofmesenchymalmarkers espe-
cially-SMA and vimentin, suggesting that down-regulation of
Id-1 andCav-1 is able to reverse their positive effect on EMT. In
addition, as shown in Fig. 2F, the si-Id-1  si-Cav-1 transfec-
tants showed the slowest migration rate (panel 4, distance ratio
to time 0 h  0.8) compared with the cells transfected with
si-ID-1 (panel 2, distance ratio to 0 h  0.4), si-CAV-1 alone
(panel 3, distance ratio to 0 h  0.3), or si-CON (panel 1, dis-
tance ratio to 0 h  0.2), suggesting that suppression of both
Id-1 and Cav-1 leads to slower cell migration. These results
support the evidence generated from overexpression experi-
ments and further suggest that Id-1 and Cav-1 synergistically
promote invasion ability of prostate cancer cells.
To study if the Id-1 Cav-1-induced E-cadherin down-reg-
ulation was regulated at the transcriptional level, we performed
RT-PCR and luciferase assay. As shown in supplemental Fig. 1,
A and B, both the mRNA level of E-cadherin and its promoter
activity were decreased in the WT-Id-1  Cav-1 transfectants
(lane 4) compared with FLAG-CT60-Id-1Cav-1 (lane 5), the
vector control (lane 1), the cells transfectedwithWT-ID-1 (lane
2), orCAV-1 (lane 3) alone, suggesting that interaction between
Id-1 and Cav-1 may contribute to transcriptional suppression
of E-cadherin expression.
The Id-1 Cav-1-induced EMT and Invasion Are Mediated
through Akt Pathway—Previously, it was reported that activa-
tion of Akt through phosphorylation was associated with
prostate cancer progression and poor clinical outcome (37, 38).
Cav-1, on the other hand, was found to promote Akt activation
in prostate cancer cells (39). Therefore, we hypothesized that
the Akt pathway may play a role in regulating the synergistic
effect of Id-1 and Cav-1 in promoting EMT in prostate cancer
cells. To test this hypothesis, we examined the expression of
p-Akt and its downstream effector p-GSK3. As shown in Fig.
3A, the expression of both p-Akt and p-GSK-3 was increased
moderately in the cells transfected with ID-1 (lanes 2 and 7) or
CAV-1 (lanes 3 and 8) alone; however, the expression of both
p-Akt and p-GSK-3 was increased significantly in the cells
transfectedwithWT-ID-1CAV-1 (lanes 4 and 9, highlighted)
compared with the vector control (lanes 1 and 6) or the cells
transfected with ID-1 (lanes 2 and 7) or CAV-1 (lanes 3 and 8)
alone. This effect was not detected in the cells transfected with
FLAG-CT60-ID-1  CAV-1 (Fig. 3A, lanes 5 and 10). These
results suggest that although overexpression of Id-1 and Cav-1
alone is able to increase the phosphorylation of Akt and GSK-
3, the interaction between Id-1 and Cav-1 synergistically pro-
motes Akt pathway activation. To further confirm the signifi-
cance of Akt phosphorylation in WT-Id-1  Cav-1-induced
EMT and cell migration, we treated the WT-ID-1  CAV-1-
transfected cells with two specific PI3K/Akt inhibitors, wort-
mannin and LY294002, and we studied their effect on the
expression of E-cadherin, -catenin, -catenin, as well as
N-cadherin and -SMA. As shown in Fig. 3B, the expression of
p-Akt and p-GSK-3was decreased after treatment with wort-
mannin (100 nM) (lane 3) and LY294002 (20 m) (lane 5),
respectively, compared with the untreated control (lanes 2 and
4). This decrease was associated with increased expression of
epithelialmarkers and down-regulation ofmesenchymalmark-
ers. In addition, fluorescent immunostaining studies also
showed that both wortmannin and LY294002 treatment pro-
FIGURE 2.Effect of Id-1 andCav-1 interactiononEMTand cellmigration inprostate cancer cells. LNCap and 22RV1 cellswere co-transfectedwithWT-ID-1
 CAV-1, FLAG-CT60-ID-1 (no-binding Id-1 mutant) CAV-1, as well as the ID-1, CAV-1, or vector alone controls. 24 h after transfection, mediumwas changed
to serum-freemedium for another 24 h.A,Western blotting analysis ofWT-Id-1, FLAG-CT60-Id-1, and Cav-1 expression in the transfectants. B, effect of Id-1 and
Cav-1 on the expression of EMT markers by Western blotting. C, immunofluorescent staining of E-cadherin and -catenin in LNCap cells. Photos were taken
under400 magnifications. D, cell migration rate examined by wound closure assay. A scraped wound was introduced on monolayer LNCap cells, and the
speed of wound closurewasmonitored at 28 h. The vertical distance between two borderlines of thewoundwasmeasured, and the distancewas set up as 1.0
at time 0 h in each cell line. Cell migration rate was calculated by dividing the distance between two borderlines at 28 h time point and time 0 h. Note that
transfection ofWT-Id-1Cav-1 promotes EMT andmigration ability of LNCap cells. E and F, effect of Id-1 andCav-1 down-regulation on the expression of EMT
markers and cell migration rate in PC3 cells. Cells were transiently transfected with Si-ID-1, Si-CAV-1, Si-ID-1  Si-CAV-1, and Si-CON, respectively, for 24 h.
Western blottingwas performedon cell lysate (E). Wound closure assaywas performedon the transfectants (F). Cellmigration ratewas calculated as described
in D.
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moted re-distribution of E-cadherin and -catenin to cell
membrane (representative results on wortmannin-treated cells
are shown in Fig. 3C). Furthermore, the speed of cell migration
was also reduced in the wortmannin-treated cells (Fig. 3D).
These results suggest that Akt activation plays a key role in the
Id-1 Cav-1-induced EMT and cell migration.
Significance of Interaction between Id-1 and Cav-1 in Protec-
tion against Taxol-induced Apoptosis—Previously, Id-1 has
been suggested as an anti-apoptotic factor against a variety of
anticancer drugs (40). To study if the interaction between Id-1
and Cav-1 played a role in the anti-apoptotic function of Id-1,
first, we treated the LNCap and 22RV1 transfectants with taxol
and examined cell viability by MTT assay. As shown in Fig. 4A,
after being exposed to three doses of taxol, different cell viabil-
ity was observed in the cells transfected with WT-ID-1 
CAV-1 (black columns) comparedwith the vector control (open
columns) and the cells transfectedwith ID-1 (columnswith hor-
izontal lines) or CAV-1 (columnswith vertical lines) alone. The
percentage of viable cells was the highest in the WT-Id-1 
Cav-1 transfectants (Fig. 4A, black columns), and the difference
reached statistical significance in the cells treatedwith two high
doses of taxol comparedwith the other cell lines (*, p 0.05). In
contrast, the FLAG-CT60-Id-1  Cav-1 transfectants (Fig.
4A, columns with diagonal lines)
showed a lower cell viability com-
paredwith the cells transfectedwith
WT-ID-1 CAV-1 (black columns,
*, p 0.05), but no significant differ-
ence was found when compared
with the cells transfected with ID-1
or CAV-1 alone (p  0.05). These
results indicate that the interaction
between Id-1 and Cav-1 seems
to provide a survival benefit in
response to taxol in prostate cancer
cells.
Activation of the Akt pathway is
reported to promote cell survival
through protection against chemo-
therapeutic drug-induced apoptosis
(41). Next, we studied if the
WT-Id-1  Cav-1-induced Akt
activation played a role in protec-
tion against taxol-induced apopto-
sis in both cell lines. As shown in
Fig. 4B, after taxol treatment, the
cells transfected with WT-ID-1 
CAV-1 (lanes 4 and 9, highlighted)
showed higher levels of p-Akt com-
pared with the vector control (lanes
1 and 6) and the cells transfected
with ID-1 (lanes 2 and 7) or CAV-1
(lanes 3 and 8) alone, whichwas cor-
related with higher expression of
Bcl-2 and decreased expression of
cleaved-caspase 3 and PARP. How-
ever, this effect was partially
reversed in the cells transfected
with FLAG-CT60-ID-1  CAV-1 (Fig. 4B, lanes 5 and 10).
These results suggest that activation of Akt is associated with
resistance to taxol-induced apoptosis in the WT-Id-1 Cav-1
transfectants. To further confirm the importance of the Akt
pathway, we treated theWT-Id-1Cav-1 cells with two PI3K/
Akt inhibitors, LY294002 and wortmannin, and we studied
whether inhibition of PI3K/Akt pathway could promote taxol-
induced apoptosis. As shown in Fig. 4C, suppression of Akt
phosphorylation (lanes 4 and 8) resulted in promotion of
caspase 3 and PARP cleavage and suppression of Bcl-2 expres-
sion (lanes 4 versus 3 and lanes 8 versus 7), and decreased cell
viability in the WT-ID-1  CAV-1-transfected cells (Fig. 4D,
*, p  0.05). These results demonstrate that Akt pathway acti-
vation plays a key role in the WT-Id-1  Cav-1-induced pro-
tection against taxol-induced apoptosis.
Id-1 Inhibits PP2A Activity through Interaction with Cav-1—
Previously, it has been reported that Cav-1 promotes Akt activa-
tion through suppression of the activity of two serine/threonine
protein phosphatases, PP1 and PP2A, by forming direct physical
interaction (39). Next, we investigated if the WT-Id-1  Cav-1-
induced Akt activation was mediated through modification of
PP2A activity. As shown in Fig. 5A, the PP2A activity was lower in
the Cav-1-transfected cells comparedwith the control (columns 3
FIGURE 3. Role of Akt pathway in WT-Id-1  Cav-1-induced EMT and cell migration in prostate cancer
cells. LNCap cells were transfected withWT-ID-1 CAV-1, FLAG-CT60-ID-1, CAV-1, and empty vector, and 24 h
after transfection, themediumwas changed to serum-freemedium for 24 h.A,Western blotting analysis of the
expression of p-Akt and p-GSK3. B,Western blotting analysis of Akt and GSK expression and EMTmarkers in
the cells treated with PI3K/Akt-specific inhibitors LY294002 (20 M) or wortmannin (100 nM). C, immunofluo-
rescent staining of E-cadherin and-catenin before and after exposure towortmannin (100 nM) in LNCap cells.
Photos were taken as described in Fig. 2C. D, effect of PI3K/Akt-specific inhibitor wortmannin (100 nM) on cell
migration. Note that Akt pathway activation is associatedwith EMT and increased cell migration, which can be
suppressed by PI3K/Akt-specific inhibitors.
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versus 1), suggesting that Cav-1 is able to inhibit PP2A activity in
prostate cancer cells as reported previously (39). In addition, in
WT-Id-1  Cav-1 transfectants (Fig. 5A, columns 4 and 8), the
PP2A activity was decreased further compared with the vector
control (columns 1 and 5) and the cells transfected with ID-1 (col-
umns 2 and 6) or CAV-1 (columns 3 and 7) alone (*, p  0.05),
suggesting that Id-1 promotes the inhibitory effect of Cav-1 on
PP2A. However, decreased PP2A activity was not the result of
alteration at PP2A protein expression levels (Fig. 5A, inserted
blots). To study whether the decreased PP2A activity in the WT-
Id-1Cav-1 transfectantswasmediated through aphysical inter-
action between PP2A and the Id-1-Cav-1 complex, we performed
immunoprecipitation. As shown in Fig. 5B, PP2Awas not precip-
itated with Id-1 when the cells were transfected with Id-1-FLAG
FIGURE 4.Effect of Id-1 andCav-1on taxol-inducedapoptosis inprostate cancer cells.Cellswere co-transfectedwithWT-ID-1CAV-1, CT60-ID-1CAV-1,
aswell as ID-1orCAV-1, vector alone controls for 24h.A, cell viability of LNCapand22RV1after exposure to taxol examinedbyMTTassay. 24hafter transfection,
cells were seeded in 96-well plates and cultured for 24 h and then treatedwith three doses of taxol in serum-freemedium, respectively, for 24 h. Note that cell
viability is higher in theWT-Id-1Cav-1 transfectants (*, p 0.05). B,Western blotting analysis of Akt and apoptosis-related proteins after exposed to taxol (10
ng/ml for LNCap and 50 ng/ml for 22RV1). After transfection for 24 h, the cells were treated with taxol in serum-free medium for another 24 h. Note that the
expression of Bcl-2 ismuchhigher in the cells transfectedwithWT-ID-1CAV-1,which is associatedwith decreased expression of cleaved caspase 3 and PARP,
comparedwith the cells transfectedwith ID-1 or CAV-1 alone and the vector control. The relative intensity of each bandwas quantified using the taxol-treated
untransfected cells as a control, which was set up as 1.0. The results are shown as the ratios between the transfected and the untransfected cells indicated at
the bottomof eachgel.C,Western blotting analysis of the expression of apoptosis-relatedproteins after exposure to PI3K/Akt-specific inhibitors LY294002 (left
panel) or wortmannin (right panel) in theWT-Id-1 Cav-1 transfectants. Note that the expression of p-Akt is decreased after treatment with wortmannin (100
nM) and LY294002 (20 M) compared with the untreated control, which is associated with the increased expression of cleaved caspase 3 and PARP. D, cell
viability of LNCap cells transfectedwithWT-Id-1 Cav-1 after exposure to taxol and LY294002 (20M) examined byMTT assay. Note that cell viability is lower
in the cells treated with both LY294002 and taxol compared with the cells treated with taxol alone (*, p 0.05).
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alone (lane 1), suggesting that there is no interaction between Id-1
andPP2A in theabsenceofCav-1.However, PP2Awasdetected in
the immunoprecipitates when the cells were transfected with
WT-ID-1-FLAG CAV-1-HA (Fig. 5B, lane 2), suggesting inter-
action between Id-1 and PP2A is mediated through its binding to
Cav-1. When we performed immunoprecipitation with anti-HA
(Fig. 5C), bothPP2Aand Id-1-FLAGproteinswere detected in the
cells transfectedwithWT-ID-1-FLAGCAV-1-HA (lane 2), sug-
gesting again a physical interaction betweenPP2Aand Id-1-Cav-1
complex. Most importantly, the PP2A level was much higher in
the WT-Id-1  Cav-1 transfectants (Fig. 5C, lane 2) compared
with the cells transfected with Cav-1-HA alone (Fig. 5C, lane 1).
These results suggest that Id-1 promotes the binding activity
betweenCav-1 andPP2A,whichmay lead to suppression of PP2A
activity.
DISCUSSION
In this study, we identified a novel Id-1 interacting protein,
Cav-1, and found that theHLHdomainof Id-1was essential for its
binding to Cav-1. In addition, we demonstrated that interaction
between Id-1 and Cav-1 was crucial in promoting Id-1-induced
EMT and protection against apoptosis in prostate cancer cells.
Furthermore, our results suggest that activation of the Akt path-
way through the Id-1-enhanced binding activity between Cav-1
andPP2Amaybe responsible for the synergistic effect of these two
proteins. Our results demonstrate Cav-1 as a direct mediator of
Id-1 signaling and provide a novel mechanism responsible for the
role of Id-1 in promoting cancer cell invasion and survival.
In addition to its well established function as a dominant
negative regulator of binding between bHLHproteins and their
targets in muscle cell differentiation (42), recent studies have
demonstrated that Id-1 can also bind to and alter the activities
of several regulatory proteins. For example, it is reported that
Id-1 binds to Ets2, a downstream effector of the MAPK path-
way, and inhibits its transcription activity on p16INK4a, leading
to inhibition of replicative senescence in young human diploid
fibroblasts (9). In addition, Id-1 is found to physically interact
with several members of the Pax transcription factor family,
leading to a loss of DNA binding by Pax proteins and hence
down-regulation of the activity of their target promoters (43).
In this study, we identified a novel Id-1-interacting non-HLH
protein, Cav-1, a primary cell membrane protein and a subunit
of caveolae that functions both in protein trafficking and signal
transduction, as well as in cholesterol homeostasis (23). The
association between caveolins and cancer dates back to the dis-
covery of caveolin-1 as a predominant phosphoprotein in v-src-
transformed embryonic chicken fibroblasts (44). Since then, a
number of reports have demonstrated that CAV-1 is not only a
target of many oncogenes such as c-MYC, H-RAS, v-ABL but is
also a regulator ofmultiple signaling pathways through physical
interaction with epidermal growth factor receptor, MEK/ERK,
and Ras-p42/44MAPKs (23). Although it has been suggested as
a tumor suppressor in several tumor types (45–47), in prostate
cancerCAV-1 is indicated to be an oncogene (31). Interestingly,
similar expression patterns were also observed in Id-1 protein
in prostate cancer (5, 29, 30). In this study, our evidence that
interaction between Id-1 and Cav-1 was essential to promote
Id-1-induced EMT and resistance to apoptosis in prostate can-
cer cells suggests that Cav-1may be amediator of Id-1 signaling
in promoting tumorigenesis. In agreement with a previous
study (43), we also found that the HLH domain of Id-1 was
essential for the physical interaction between Id-1 and Cav-1
(Fig. 1E, left panel); however, single pointmutations of theHLH
domain were not sufficient to abolish the binding activity
between these two proteins (Fig. 1E, right panel), suggesting the
integrity of theHLHdomain is important for the physical inter-
action between Id-1 and Cav-1. However, unlike the previously
reported dominant negative effect of Id-1 on the transcription
activity of its binding partners (42), the interaction between
Id-1 andCav-1 led to activation of the Akt pathway and promo-
tion of EMT in prostate cancer cells (Figs. 2 and 4).
Activation of Akt pathway is one of the most frequently
reported phenotypes in advanced cancers (41). In this study,
our results that the Id-1-induced EMT and protection against
apoptosis was mediated through activation of the Akt pathway
(Figs. 2–4) suggest a novel molecular pathway that regulates
the oncogenic effect of Id-1. As discussed previously, activation
of Akt pathway is reported to play a positive role in the progres-
sion of prostate cancer (37, 38). It is possible that high levels of
Id-1 in the advanced prostate cancer cells may lead to promo-
tion of Akt activation, which provides a survival advantage for
cancer progression. In addition, in this study, we also found that
interaction between Id-1 and Cav-1 was essential for the Id-1-
induced Akt activation (Fig. 3A). Because Cav-1 expression is
also reported to be associated with progression of prostate can-
cer (31), it is tempting to speculate that the presence of high
levels of Id-1 and Cav-1 in prostate cancer cells may be able to
form a complex that may facilitate activation of the Akt path-
way. This hypothesis is supported by our evidence that theWT-
FIGURE 5. Effect of Id-1 on PP2A activity and its interaction with Cav-1.
A, PP2A activity assay. Note that the activity of PP2A is significantly decreased
in the cells transfected withWT-ID-1 CAV-1 compared with the cells trans-
fected with Id-1 or Cav-1 alone and the vector control (*, p 0.05). B, immu-
noprecipitation analysis of interaction between Id-1 and PP2A. Cell lysates
were immunoprecipitated with anti-FLAG and blotted with anti-PP2A,
anti-HA, and anti-FLAG, respectively. C, immunoprecipitation analysis of
interaction between Cav-1, Id-1, and PP2A in LNCap cells. Cell lysates were
immunoprecipitated (IP) with anti-HA and blotted with anti-PP2A, anti-
HA, and anti-FLAG, respectively.
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Id-1  Cav-1-induced Akt pathway activation is the result of
the Id-1 enhanced binding activity between Cav-1 and PP2A
(Fig. 5). Previously, it has been reported that Cav-1 activates
Akt through inhibition of PP2A activity through physical inter-
action, which leads to dephosphorylation of p-Akt (39). In this
study, we found that Id-1was able to promote the binding activ-
ity between Cav-1 and PP2A leading to synergistic suppression
of the phosphatase activity of PP2A (Fig. 5,B andC), whichmay
in turn result in increased Akt phosphorylation. Because the
two prostate cancer cell lines used in this study contained dif-
ferent PTEN status (PTEN is mutated in LNCap cells (48) and
22RV1 contains a wild type PTEN (49)), the WT-Id-1  Cav-
1-induced Akt activation may not be mediated through PTEN-
dependent pathways.
Recently, it has been reported that GSK, a tumor suppressor,
can be inactivated through phosphorylation by several onco-
genic signals, such as PI3K/Akt, MAPK, and Wnt, which leads
to EMT and promotion of cell invasion (50). In this study, we
also observed an increased expression of p-GSK3, an indicator
of GSK3 inactivation, in the cells transfected withWT-Id-1
Cav-1 (Fig. 3A), and it is possible that the Cav-1-mediated Akt
activation in the Id-1-overexpressing cells may also lead to
inactivation of GSK3. Previously, it is suggested that GSK3
inactivation leads to nuclear expression of the E-cadherin
suppressor Snail (51). In this study, we found a decreased
E-cadherin transcription in the WT-Id-1  Cav-1 transfec-
tants (supplemental Fig. 1, A and B), and it is speculated that
down-regulation of E-cadherin expression may be the result
of Snail activation induced by the decreased GSK3 activity,
which in turn may also contribute to Id-1-induced EMT in
prostate cancer cells.
In summary, our study demonstrates an Id-1 binding part-
ner, Cav-1, and suggests a novel molecular mechanism that
mediates the function of Id-1 in promoting prostate cancer pro-
gression through activation of the Akt pathway leading to pros-
tate cancer cell invasion on one hand and resistance to antican-
cer drug-induced apoptosis on the other hand.
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